LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN) invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00 p.m. ET on Wednesday, April 23, 2014. The meeting will be held at the company's headquarters located at 3 Forbes Road, Lexington, MA 02421. Registration for attendees starts at 4:30 p.m. ET.
The company will also broadcast the meeting via a virtual stockholder meeting. Instructions on how to participate and demonstrate proof of stock ownership are posted at www.virtualshareholdermeeting.com/Agenus2014.
A live webcast will be accessible from the company’s website at www.agenusbio.com/webcast/ and will be archived and available for replay within twenty-four hours after the meeting.
Agenus is an immuno-oncology company developing a portfolio of checkpoint modulators, heat shock protein vaccines and adjuvants. Agenus’ checkpoint modulator programs target GITR, OX40, CTLA-4, LAG-3, TIM-3 and PD-1. The company’s proprietary discovery engine Retrocyte Display® is used to generate fully human therapeutic antibody drug candidates. The Retrocyte Display platform uses a high-throughput approach incorporating full-length IgG format human antibody libraries expressed in mammalian B-lineage cells. Agenus’ heat shock protein vaccines for cancer and infectious disease are in Phase 2 studies. The company’s QS-21 Stimulon® adjuvant platform is extensively partnered with GlaxoSmithKline and Janssen, and includes several candidates in Phase 3 trials. Among Agenus and its partners, 22 programs are in clinical development. For more information, please visitwww.agenusbio.com, or connect with the company on Facebook, LinkedIn, Twitter and Google+.
QS-21 Stimulon and Retrocyte Display are registered trademarks of Agenus and its subsidiaries.